Treatment of Atrial Fibrillation and Venous Thromboembolism with Factor Xa Inhibitors in Severely Obese Patients.

BACKGROUND

A paucity of data exists to support the use of factor Xa inhibitors in severely obese patients with a weight ≥ 150kg or BMI ≥ 50 kg/m

OBJECTIVES

The purpose of this study is to evaluate whether factor Xa inhibitors are as safe and effective as warfarin for the treatment of atrial fibrillation (AF) and/or venous thromboembolism (VTE) in individuals with a BMI ≥ 50 kg/m

PATIENTS / METHODS

This was a multicenter retrospective cohort study of severely obese adult patients with AF and/or VTE treated with a factor Xa inhibitor or warfarin. The primary effectiveness outcome was a composite odds of stroke, systemic embolism or VTE; the primary safety outcome was odds of major bleeding. Secondary outcomes included incidence of stroke or systemic embolism, VTE, major bleeding, clinically relevant non-major bleeding, all-cause mortality, change in anticoagulation and total number of hospital encounters. Outcomes were assessed for 12 months following initiation of study drug.

RESULTS

A total of 1,736 patients were included. The mean weight and BMI of the overall cohort was 164.4 kg and 54.6 kg/m

CONCLUSIONS

These data suggest that apixaban and rivaroxaban are safe and effective alternatives to warfarin for the treatment of AF and/or VTE in individuals with a BMI ≥ 50 kg/m

Informations de copyright

Copyright © 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.